1. Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy 
Yuh-Min Chen, MD, PhD, Reury-Perng Perng, MD, PhD, Jen-Fu Shih, MD, Chun-Ming Tsai, MD, Jacqueline Whang-Peng, MD 
Journal of Thoracic Oncology 
Volume 1, Issue 6, Pages (July 2006)
DOI: /S (15)
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Percentage of grade 3 or 4 leukopenia (A), thrombocytopenia (B), and fatigue (C) per patient in different treatment regimens. A: Docetaxel plus ifosfamide was significantly more toxic than all the other regimens (p < 0.001, < 0.001, < 0.001, 0.042, < 0.001, < 0.001, 0.018, < 0.001, respectively). B: Gemcitabine-containing regimens, such as single-agent gemcitabine, docetaxel plus gemcitabine, and vinorelbine plus gemcitabine, induced significantly more severe thrombocytopenia than other regimens. C: Docetaxel 40 mg/m2 and vinorelbine plus cisplatin induced more frequent severe fatigue than other regimens. Gem, gemcitabine; D35, docetaxel 35 mg/m2 weekly schedule; D40, docetaxel 40 mg/m2 weekly schedule; D75, docetaxel 75/m2 every 3 weeks schedule; Gef, gefitinib; D+I, docetaxel plus ifosfamide; D+G, docetaxel plus gemcitabine; V+G, vinorelbine plus gemcitabine; V+C, vinorelbine plus cisplatin.
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) )
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions